[go: up one dir, main page]

PL442757A1 - Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition - Google Patents

Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition

Info

Publication number
PL442757A1
PL442757A1 PL442757A PL44275722A PL442757A1 PL 442757 A1 PL442757 A1 PL 442757A1 PL 442757 A PL442757 A PL 442757A PL 44275722 A PL44275722 A PL 44275722A PL 442757 A1 PL442757 A1 PL 442757A1
Authority
PL
Poland
Prior art keywords
auranofin
syrosyngopine
weight
pharmaceutical composition
composition
Prior art date
Application number
PL442757A
Other languages
Polish (pl)
Inventor
Jerzy Gubernator
Adrianna Zygmunt
Wiesław Szeja
Tomasz Cichoń
Ryszard Smolarczyk
Original Assignee
Zakład Badawczo-Produkcyjny Syntex Spółka Z Ograniczoną Odpowiedzialnością
Uniwersytet Wrocławski
Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie-Państwowy Instytut Badawczy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakład Badawczo-Produkcyjny Syntex Spółka Z Ograniczoną Odpowiedzialnością, Uniwersytet Wrocławski, Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie-Państwowy Instytut Badawczy filed Critical Zakład Badawczo-Produkcyjny Syntex Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL442757A priority Critical patent/PL442757A1/en
Publication of PL442757A1 publication Critical patent/PL442757A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna zawierająca auranofinę charakteryzująca się tym, że zawiera: 1,0 - 99% rozpuszczalnika organicznego, 0,1 - 10,0% wagowych auranofiny i syrosyngopiny we wzajemnym stosunku molowym od 3:1 do 1:3 ewentualnie 0 - 3,0% substancji konserwujących, i wodę dopełniającą do 100% i charakteryzująca się tym, że stanowi roztwór w albuminie ludzkiej zawierający: 1,0 - 50,0% albuminy 0,1 - 10,0% wagowych auranofiny i syrosyngopiny we wzajemnym stosunku molowym od 3:1 do 1:3 ewentualnie 0 - 3,0% substancji konserwujących, i wodę dopełniającą do 100% lub podobny roztwór wodny oraz charakteryzująca się tym, że roztwory auranofiny i syrosyngopiny są zawarte w liposomie razem lub oddzielnie i zawiera: 1,0 - 30,0% wagowych fosfolipidów i pegylowanych fosfolipidów, 0,1 - 2% wagowych auranofiny i syrosyngopiny w stosunku molowym od 3:1 do 1:3 buforowany roztwór wodny uzupełniający do 100%. Zgłoszenie obejmuje też zastosowanie przedmiotowej kompozycji farmaceutycznej i produkt leczniczy zawierający tę kompozycję.The subject of the application is a pharmaceutical composition containing auranofin characterized by the fact that it contains: 1.0 - 99% of organic solvent, 0.1 - 10.0% by weight of auranofin and syrosyngopine in a mutual molar ratio from 3:1 to 1:3 or 0 - 3.0% preservatives, and water making up to 100% and characterized by being a solution in human albumin containing: 1.0 - 50.0% albumin 0.1 - 10.0% by weight of auranofin and syrosyngopine in a mutual ratio molar from 3:1 to 1:3 optionally 0 - 3.0% of preservatives, and water making up to 100% or a similar aqueous solution and characterized in that the auranofin and syrosyngopine solutions are contained in the liposome together or separately and contains: 1 ,0 - 30.0% by weight of phospholipids and pegylated phospholipids, 0.1 - 2% by weight of auranofin and syrosyngopine in a molar ratio from 3:1 to 1:3 buffered aqueous solution making up to 100%. The application also covers the use of the pharmaceutical composition in question and the medicinal product containing this composition.

PL442757A 2022-11-08 2022-11-08 Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition PL442757A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442757A PL442757A1 (en) 2022-11-08 2022-11-08 Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442757A PL442757A1 (en) 2022-11-08 2022-11-08 Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition

Publications (1)

Publication Number Publication Date
PL442757A1 true PL442757A1 (en) 2024-05-13

Family

ID=91070344

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442757A PL442757A1 (en) 2022-11-08 2022-11-08 Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition

Country Status (1)

Country Link
PL (1) PL442757A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
WO2021058967A1 (en) * 2019-09-27 2021-04-01 Varsity Pharmaceuticals Limited Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
WO2022033459A1 (en) * 2020-08-10 2022-02-17 萧乃文 Use of double non-oncology drug in preparation of pharmaceutical composition for treating cancers
WO2022142131A1 (en) * 2020-12-30 2022-07-07 中山大学 Anti-cancer composition containing auranofin and sulfhydryl compound and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
WO2021058967A1 (en) * 2019-09-27 2021-04-01 Varsity Pharmaceuticals Limited Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
WO2022033459A1 (en) * 2020-08-10 2022-02-17 萧乃文 Use of double non-oncology drug in preparation of pharmaceutical composition for treating cancers
WO2022142131A1 (en) * 2020-12-30 2022-07-07 中山大学 Anti-cancer composition containing auranofin and sulfhydryl compound and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KSHATTRY S. I IN., „CYSTINE DEPLETING HUMAN ENZYME COMBINED WITH AURANOFIN SYNERGISTICALLY INHIBITS PANCREATIC CANCER CELL GROWTH IN VITRO AND IN VIVO", CANCER RES (2018) 78 (13_SUPPLEMENT): 3963 *

Similar Documents

Publication Publication Date Title
BR112017018443A2 (en) ? oil-in-water emulsion and its use, cosmetic, dermatological or pharmaceutical preparation, or cleaning preparation and / or home care preparation and industry?
BRPI0700148A (en) low viscosity, long-lasting, cold preparation cosmetic emulsions
EA201792559A1 (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION
EA200601776A1 (en) METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION
MA48461A (en) EXCIPIENTS TO REDUCE THE VISCOSITY OF ANTIBODY FORMULATIONS AND FORMULATION COMPOSITIONS
PA8553101A1 (en) FORMULATIONS IN COMBINATION OF PROPANOL-AMINA DERIVATIVES SUBSTITUTED WITH ARILO, TOGETHER WITH OTHER ACTIVE SUBSTANCES AND ITS USE
PE20171334A1 (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
DE60216077D1 (en) TOPICAL PRODUCT WITH VISUAL INDICATOR
PL442757A1 (en) Pharmaceutical composition containing auranofin, its use and the medicinal product containing this composition
MX2022003901A (en) Personal care composition preservatives level optimization.
ES2187019T3 (en) CONSERVATION COMPOSITION THAT INCLUDES A YODOPROPINIL BUTIL CARBAMATO AND A PHENOXYETHANOL.
ATE294226T1 (en) COMPOSITIONS OF A WOOL INTERNAL FAT EXTRACT AND THE USE THEREOF FOR THE PRODUCTION OF SKIN CARE AND TREATMENT PRODUCTS
ES2063411T3 (en) PARTICULARLY COSMETIC OR DERMATOLOGICAL COMPOSITION OF SLIMMING OR ANTI-CELLULITE ACTION CONTAINING EXTRACTS OF GLUE IN A LIPOSOMAL FORM.
CN105963180A (en) Healthcare wet tissue
DK1893237T3 (en) Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active substance
TW200628467A (en) Novel sulfamides
ES2991481T3 (en) Mild antimicrobial foam soap containing malic acid and levulinic acid
EP4205737A4 (en) COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF INFLAMMATORY DISEASES OR IMMUNE DISEASES COMPRISING GANCAONIN N AS ACTIVE INGREDIENT
EP1757272A3 (en) Drug-release system and its use
AR029829A1 (en) USE OF A CASEINE DERIVATIVE FOR THE PREPARATION OF COSMETIC, PHARMACEUTICAL AND VETERINARY COMPOSITIONS AND THE PREPARED COMPOSITIONS ASUS, USEFUL TO INHIBIT THE ADHESION OF THE PATHOGRAPHIC FLORA TO THE SKIN
EP3701933A4 (en) OIL-IN-WATER EMULSION COMPOSITION AND COSMETIC PREPARATION
ES2627852T3 (en) Use of substituted methoxyalkoxyphenyl alkyl derivatives as preservative, preservation method, compounds and composition
FR3073395B1 (en) ANTIMICROBIAL MIXTURE CONTAINING 4- (3-ETHOXY-4-HYDROXYPHENYL) BUTAN-2-ONE AND 1,2-DECANEDIOL, AND COSMETIC COMPOSITION CONTAINING THE SAME
TH85154A (en) Improve the composition of cosmetic products
DE602006019311D1 (en) TREATMENT OF LENGTH-DEPENDENT NEUROPATHY